Trial Profile
A Study to identify the predictive Biomarkers of response to PD-1 therapy (nivolumab, pembrolizumab, and atezolizumab) in patients with Non-small-cell-lung-cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jun 2017
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology